NAD+ research: separate the molecule, the precursor and the outcome

NAD+ is a biological participant, not an outcome

NAD+ and NADH are the oxidised and reduced forms of a coenzyme pair involved in cellular metabolism. NAD+ also participates in reactions beyond redox metabolism. These biological roles explain scientific interest; they do not establish that supplying a particular product improves health or extends lifespan.

The distinction between the two forms helps explain their function. NAD+ accepts electrons during metabolic reactions, becoming NADH. NADH can then supply electrons to the mitochondrial respiratory chain, which helps power ATP production. Cells continually recycle the pair; NAD+ is not itself a package of energy delivered directly to tissues.

Other reactions consume NAD+ rather than simply switching it between oxidised and reduced forms. Sirtuins use it in reactions that modify proteins, while PARP enzymes use it in cellular responses to DNA damage. Participation in these pathways does not mean that increasing NAD+ necessarily improves every process they regulate.

A precursor study tests a precursor

Nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) and direct NAD+ are different interventions. A trial of oral NR cannot validate an injected or nasal NAD+ formulation. Route, formulation, population and duration remain part of the result.

NR and NMN are precursors that cells can use in pathways producing NAD+. Their relationship to the coenzyme explains why researchers measure NAD-related metabolites after administration. It does not make the compounds interchangeable: a shared downstream molecule is not evidence of identical absorption, tissue exposure or clinical effects.

Biomarkers and clinical endpoints can diverge

In a randomised pilot published online in 2023, researchers studied oral NR in 20 older people with mild cognitive impairment over 10 weeks. Blood NAD+ rose approximately 2.6-fold, but cognition did not improve over the study period. The experiment therefore supported a biochemical response to NR without demonstrating the hoped-for cognitive benefit. Original pilot study.

A July 2026 phase-II pilot provides a useful second example. Among 42 completers—22 receiving NR and 20 placebo—blood NAD+ approximately doubled over 12 weeks. There was no improvement in the primary cognitive outcome, total cerebral blood flow or blood pressure. Exploratory findings in individual brain regions should not be recast as an established clinical benefit. Phase-II pilot.

These small, short studies do not settle every possible application of NR. Equally, their limitations cannot turn an unobserved benefit into a positive result. Blood measurements also do not directly establish NAD+ availability within particular brain cells or their mitochondria.

Read claims in this order

Identify the administered substance first, then the study population, comparator and measured endpoint. Finally, check whether the preparation and route match the product being discussed. This keeps evidence about metabolism, biomarkers and clinical outcomes from being merged into a single anti-ageing promise.

Claims about a combination, a delivery route or long-term benefit each need evidence directed at that question. The useful finding here is specific: oral NR changed a blood biomarker in these studies, without demonstrated cognitive improvement.